[Specific antitumor effect of lymphokine-activated lymphocytes obtained from tumor-bearing mice after intratumoral injection of interleukin-2 (IL-2)].
Specific antitumor effects of lymphokine-activated lymphocytes obtained from tumor-bearing mice after intratumoral injection of IL-2 were studied. Inbred C57BL/6 mice bearing syngeneic tumor (B16,3LL) were used. After intratumoral consecutive injection of recombinant human IL-2 (rhIL-2), the splenocytes of these mice were cultured with rhIL-2 and the effector cells were obtained. Specific antitumor effects of the effector cells against B16 and 3LL were studied in vitro and in vivo. Surface antigens of them were also analysed. The results were as follows: 1) 51Cr-release test under coculture with rhIL-2 showed that cytotoxicity against the host tumor cells with the effector cells became specifically augmented. 2) Winn assay showed specific inhibition of the host tumor growth with the effector cells. 3) Adoptive transfer of te effector cells specifically diminished the size of the host tumor and prolonged the life span of the mice. 4) The lymphokine-activated lymphocytes obtained from normal and non-treated tumor-bearing mice had no specific antitumor effect. 5) The analysis of the surface antigens indicated that Thy1.2+L3T4+ T cells increased in the effector cells as the specific cytotoxicity of them were augmented, while in the effector cells from normal and non-treated tumor-bearing mice, Thy1.2+L3T4+ T cells decreased and Thy1.2+Lyt2+ T cells increased.
Takahashi
M
M
Second Department of Surgery, Yokohama City University School of Medicine, Japan.
D000818:Animals; D000954:Antigens, Surface / Q000032:analysis; D003602:Cytotoxicity, Immunologic; D016219:Immunotherapy, Adoptive; D015552:Injections, Intralesional; D007376:Interleukin-2 / Q000008:administration & dosage / Q000494:pharmacology*; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000276:immunology*; D011994:Recombinant Proteins / Q000494:pharmacology; D013154:Spleen / Q000276:immunology; D014407:Tumor Cells, Cultured
D000954:Antigens, Surface; D007376:Interleukin-2; D011994:Recombinant Proteins